Nan Fung Group Holdings Ltd
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), Nan Fung Group Holdings Ltd reported 35 stock positions worth $122.6 million. Its top holding was Harmony Biosciences (HRMY) at 10.0% of the portfolio, followed by Oculis (OCS, 8.0%) and Illumina (ILMN, 7.7%). Compared with Q4 2024, it opened 1 new position, sold out of 1, added to 9 and reduced 2. The biggest buy was a new position in Protagonist Therapeutics (PTGX) and the biggest sale an exit from Rubrik Class A (RBRK).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $122.6M (Q1 2025)
- SEC Filing
- 0001012975-25-000235 ↗ filed May 14, 2025
Holdings Value
Holdings 35 stocks · $122.6M
| HRMY Harmony Biosciences Holdings | 9.98% | 368,665 | $12.2M | No change |
| OCS Oculis Holding AG | 7.99% | 514,702 | $9.8M | Add +17.9% |
| ILMN Illumina Inc. | 7.71% | 119,196 | $9.5M | No change |
| VRNA Verona Pharma Ltd. | 7.66% | 147,990 | $9.4M | Add +11.2% |
| ZLAB Zai Lab Ltd.-ADR | 7.48% | 253,675 | $9.2M | Add +8.0% |
| MIRM Mirum Pharmaceuticals Inc. | 5.39% | 146,765 | $6.6M | Add +17.1% |
| PTGX Protagonist Therapeutics Inc. | 4.79% | 121,400 | $5.9M | New |
| SLNO Soleno Therapeutics Inc. | 4.64% | 79,650 | $5.7M | No change |
| XENE Xenon Pharmaceuticals Inc. | 4.34% | 158,605 | $5.3M | Add +48.7% |
| MRUS Merus NV | 4.12% | 120,038 | $5.1M | No change |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 3.49% | 15,722 | $4.3M | Reduce -21.4% |
| REPL Replimune Group Inc. | 3.29% | 414,246 | $4.0M | Add +28.8% |
| MDGL Madrigal Pharmaceuticals Inc. | 3.21% | 11,872 | $3.9M | Add +6.7% |
| INCY Incyte Corp. | 2.91% | 59,022 | $3.6M | Reduce -11.9% |
| RXRX Recursion Pharmaceuticals-A | 2.87% | 664,610 | $3.5M | No change |
| TRML Tourmaline Bio Inc. | 2.82% | 227,090 | $3.5M | Add +21.4% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.12% | 49,120 | $2.6M | No change |
| EXEL Exelixis Inc. | 1.93% | 64,200 | $2.4M | No change |
| GERN Geron Corp. | 1.78% | 1,373,550 | $2.2M | No change |
| ASND Ascendis Pharma A/S | 1.73% | 13,600 | $2.1M | No change |
| LAB Standard Biotools Inc. | 1.66% | 1,883,179 | $2.0M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 1.45% | 154,522 | $1.8M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 1.40% | 102,984 | $1.7M | No change |
| ARGX Argenx SE - ADR | 1.35% | 2,800 | $1.7M | Add +551.2% |
| KYMR Kymera Therapeutics Inc. | 0.69% | 30,875 | $845K | No change |
| RVMD Revolution Medicines Inc. | 0.56% | 19,253 | $681K | No change |
| RANI Rani Therapeutics Holdings Class A | 0.51% | 493,584 | $622K | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 0.48% | 68,943 | $585K | No change |
| CLYM Climb Bio Inc. | 0.46% | 463,654 | $566K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.38% | 1,166,952 | $467K | No change |
| TRDA Entrada Therapeutics Inc. | 0.36% | 49,082 | $444K | No change |
| DBVT DBV Technologies SA-Spon ADR | 0.21% | 37,095 | $253K | No change |
| BOLT PROJS HLDGS INC | 0.20% | 811,952 | $250K | No change |
| AFMDQ Affimed NV | 0.02% | 37,247 | $27K | No change |
| ALXO Alx Oncology Holdings Inc. | 0.02% | 41,950 | $26K | No change |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
| PTGX Protagonist Therapeutics Inc. | New | 4.79% | +4.79 |
| VRNA Verona Pharma Ltd. | Add +11.2% | 7.66% | +2.38 |
| ZLAB Zai Lab Ltd.-ADR | Add +8.0% | 7.48% | +2.21 |
| OCS Oculis Holding AG | Add +17.9% | 7.99% | +1.64 |
| ARGX Argenx SE - ADR | Add +551.2% | 1.35% | +1.13 |
| MIRM Mirum Pharmaceuticals Inc. | Add +17.1% | 5.39% | +0.96 |
| XENE Xenon Pharmaceuticals Inc. | Add +48.7% | 4.34% | +0.76 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +6.7% | 3.21% | +0.27 |
| REPL Replimune Group Inc. | Add +28.8% | 3.29% | −0.04 |
| TRML Tourmaline Bio Inc. | Add +21.4% | 2.82% | −0.43 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |